US EditionPublished • loading... • Updated
AGC Biologics to Manufacture AAVantgarde’s Dual-Vector Gene Therapies for Inherited Retinal Disorders
Summary by The Bakersfield Californian
3 Articles
3 Articles
AGC Biologics to Manufacture AAVantgarde’s Dual-Vector Gene Therapies for Inherited Retinal Disorders
On the heels of AAVantgarde closing a Series B financing round, AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics’ latest advancement in the adeno-associated virus market. Under this agreement, AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s two novel candidates designed to address progressive and irreversible vision loss where there are currently no…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
